Advanced Pharma Intelligence The biopharmaceutical industry is at a pivotal time in medical discovery, which has enormous potential to further revolutionize the treatment of costly and debilitating diseases like Alzheimer’s, cancer, heart disease, and hepatitis C. Our ability to harness recent scientific advances continues to accelerate, and the potential benefits to patients are becoming clearer.
Much of this progress is attributed to a deeper, molecular-level understanding of all different kinds of diseases. There are more than 7,000 medicines in clinical development around the world right now, more than ever before, and 70% of medicines have the potential to be best-in-class therapies. From 2000 to 2015, this pipeline spawned more than 550 new medicines that were approved by the US Food and Drug Administration (FDA).
A new approach in cancer therapy has the potential to be broadly applicable across a wide range of cancers. Researchers have long understood the metabolism of cancer cells is aggressively ramped up relative to normal cell metabolism, enabling mutated cancer cells to grow exponentially at the expense of healthy surrounding tissue. A number of investigative medicines in clinical development aim to disrupt cancer cell metabolism and impede cell growth.
Some of these medicines target genetic mutations involved in metabolic processes that may be more prevalent in certain cancers. Other cancer metabolism-targeting drugs in development aim to disrupt metabolic functions that occur in most types of cancer. The latter approach works by cutting off the energy supply to cancer cells, causing the cells to die. Medicines targeting cancer metabolism are being explored by researchers to address a range of different cancers, including acute myeloid leukaemia, glioma, lung cancer, pancreatic cancer, breast cancer, and many other blood cancers and solid tumors; these medicines and the many being explored in combination with other cancer therapies offer tremendous hope for patients.
The global Pharma and Biotech Industry ranks high among the most profitable industries in the world. The current market is estimated to grow from $800 Billion USD to $1.2 Trillion by 2022. The market cap of the top 100 pharmaceutical companies is $2.2 Trillion dollars.
Who we are, and what we do
- Seasoned team of industry experts based in Zug, Switzerland
- Combining industry, pricing, software and trading knowledge
- Translate global data into a single non-biased fact-based platform
- Seek and identify the highest profitable molecules in clinical development
The Problem
- There are 7,000 drugs in development, and 70% of those will be first in class3
- Only 2 out of 10 drugs match or exceed R&D investment4
- Evaluate Pharma lowers projections for next 5 years by $390 billion mainly due to pricing pressure4
- Forecasting is becoming more and more complex due to bio-markers and orphan indications
- Trading and stock price volatility has been increasing as a result
Our Solution
- Single global drug pricing platform
- Disease and epidemiology database
- Drug forecasting platform
- Integrated – drug pricing and forecasting system through Blockchain
- Securities trading signals
Our Solution
- Single global drug pricing platform
- Disease and epidemiology database
- Drug forecasting platform
- Integrated – drug pricing and forecasting system through Blockchain
- Securities trading signals
The BioNT Token
- 140,000,000 BioNT Tokens
- 5-year lock up of unsold tokens
- 50% of annual software revenues for token buy back a. Those tokens will be deleted after buyback
More Info :
| WEBSITE | WHITEPAPER |
|---|
https://bitcointalk.org/index.php?action=profile;u=886049
